Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more
sensitive to the drug.
PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and
temozolomide in treating patients with relapsed glioblastoma.
OBJECTIVES:
Primary
- To determine whether olaparib crosses the blood-brain barrier (BBB) and achieves tumor
penetration in patients with relapsed glioblastoma. (Stage 1)
- To determine the safety and tolerability of the combination of olaparib and temozolomide
in patients with relapsed glioblastoma. (Stage 2)
Secondary
- To assess BBB disruption and BBB permeability in patients with relapsed glioblastoma.
(Stage 1 and stage 2 maximum-tolerated dose [MTD] expansion cohort)
- To assess the possible anti-tumor activity of the combination of olaparib and
temozolomide in patients with relapsed glioblastoma. (Stage 2)
Tertiary
- To assess biological markers as possible predictors of olaparib efficacy in patients
with glioblastoma.
- To optimize techniques for measuring DNA damage responses to PARP inhibition in tumor
tissue.
- To determine plasma concentration of olaparib at the time of surgery in patients with
glioblastoma.
- To evaluate the PARP inhibition at the time of surgery in peripheral blood mononuclear
cells (PBMCs).
OUTLINE: This is a multicenter, dose-escalation study.
- Stage 1: Patients receive fixed-dose oral olaparib twice daily for 3 days prior to
resection and then receive a dose of oral olaparib on the morning of the resection.
After the surgical resection, patient receive standard of care treatment. Patients
undergo dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and
diffusion-weighted imaging (DWI) scans to assess the disruption and permeability of the
blood-brain barrier (BBB).
Stage 1 is complete and it was proven that olaparib can cross the BBB and achieve tumour
penetration in glioblastoma patients.
- Stage 2: Patients receive escalating doses of oral olaparib once or twice daily for 3
days prior to resection and then receive a dose of oral olaparib on the morning of the
resection. After recovery from surgery, patients receive oral olaparib once or twice
daily and oral temozolomide once daily on days 1-42. Treatment repeats every 8 weeks for
up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients
may receive 3 additional courses of treatment in the absence of disease progression.
Once the maximum tolerated dose (MTD) is established, 10 more patients are treated at the MTD
as stage 2 MTD expansion cohort. These patients also undergo DCE-MRI and DWI scans.
All patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic
studies.
After completion of study treatment, patients are followed up for 28 days and then monthly
until resolution of study drug-related adverse events.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 |